Therapeutic targeting of CD40L-Mac-1 in inflammatory disease, in particular atherosclerosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/586653

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Atherosclerosis is a major burden for human health resulting in myocardial infarction-stroke. We have previously identified a novel interaction between two adhesion molecules, CD40L and Mac-1, which mediates leukocyte adhesion to endothelial cells being a major determinant of atherosclerotic plaque development. We are now developing blocking peptides and recombinant antibodies thereby exploring various anti-inflammatory- anti-atherosclerotic strategies, targeting both Mac-1 and CD40L.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $559,642.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cardiology (incl. Cardiovascular Diseases)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

CD40L | Mac-1 | acute coronary syndromes | atherosclerosis | inflammation | leukocytes | peptides-peptidomimetics | single-chain antibodies

Related Links